Veglin has shown promising results in recent clinical trials in Southern California. Researchers have concluded that Veglin can slow cancer cells from secreting a family of proteins called Vascular Endothelial Growth Factors (VEGF). As tumors get larger, they need to grow their own blood vessels in order to become malignant. As a result, tumors signal nearby blood vessels to develop new blood vessels around them in a process called angiogenesis. VEGF is a critical ingredient to the growth of these new blood vessels. People inflicted with mesothelioma have much higher levels of VEGF than sufferers of other types of cancer.
